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http://dx.doi.org/10.1016/j.pedneo.2Background: This study was carried out in Chang Gung Memorial Hospital-Kaohsiung Medical
Center, Taiwan, with the aim of reviewing the characteristics and the outcome of liver trans-
plantation (LT) in children with Alagille syndrome (AGS).
Methods: We performed a retrospective analysis of transplant records of children diagnosed
with AGS and undergoing LT between 1987 and 2010.
Results: Nine patients underwent living donor LT. Cholestasis and characteristic facies were
seen in all patients. Posterior embryotoxon was seen in 4/9 (44.4%), butterfly vertebrae in
3/9 (33.3%), heart defect (pulmonary stenosis in 2) in 3/9 (33.3%), and renal disease in 2/9
(22.2%) patients. Five cases had cholestasis prior to the age of 60 days, whereas four cases
had cholestasis after 60 days of age. Iminodiacetic acid scans showed no excretion of isotope
into the bowel in four cases and suggested a false diagnosis of biliary atresia. All patients un-
derwent diagnostic laparotomy and liver biopsy. Results of liver biopsy showed characteristic
features of paucity of interlobular bile ducts in all patients. Kasai portoenterostomy was not
performed in any patient prior to being referred for LT. The mean age at the time of LT was
4.6 years. The 5-year overall survival rate after living donor LT was 88.9%.t of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of
, Kaohsiung 83305, Taiwan.
om.tw (M.-M. Tiao).
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136 C.-N. Lee et alConclusion: Our conclusion is that the clinical features of AGS are informative. In addition, his-
tological confirmation is important in the diagnosis. AGS children with severe liver disease had
good prognoses with LT.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Alagille syndrome (AGS), biliary atresia, choledochal cysts,
and gallbladder disease can be associated with similar
clinical symptoms, laboratory findings, and radiographic
findings that make accurate diagnosis difficult.1 All of these
conditions/diseases can be associated with high morbidity
and mortality if the diagnosis and treatment are not accu-
rately provided or they are delayed.1
AGS is an autosomal dominant disorder.2 In addition to
the liver, AGS is also associated with abnormalities
involving the heart, eye, skeleton, and kidney, and the
increasing importance of abnormalities in the central ner-
vous system is being recognized.2,3 Cholestasis associated
with AGS may, in a few cases, be extremely severe and
result in a major impairment in the quality of life during
early childhood, eventually resulting in cirrhosis.4 It is re-
ported that pruritus and xanthomata disappear and results
of liver function tests are normal in 83.3% of AGS children
after living donor liver transplantation (LDLT).4 The overall
20-year average survival rate is 70% after LDLT.5 These re-
sults indicate that the quality of life can be improved after
LT in children with a severe hepatic form of AGS.4
In this study,we reviewedour experiencewith AGS, its signs
and symptoms, diagnosticmodalities, andoutcomeafter LDLT.2. Patients and Methods
The medical records of patients diagnosed as AGS and those
AGS patients who underwent LDLT at Chang Gung Memorial
Hospital-Kaohsiung Medical Center, Taiwan, between 1987
and 2010 were retrospectively reviewed. This study was
approved by the Technical Review Board and Ethics Com-
mittee of Chang Gung Memorial Hospital.
All patients had at least three of the five major clinical
features (chronic cholestasis, congenital heart disease,
“butterfly-like” vertebrae, posterior embryotoxon, and
peculiar facies). End-stage liver disease was clinically
defined by the following laboratory tests: serum bilirubin
concentration >17.0 mg/dL and prolonged prothrombin
time despite judicious treatment with parenteral vitamin K.
Investigations for portal hypertension included ultrasonog-
raphy and computed tomography angiography and/or
conventional angiography. Therapy included various anti-
pruritus drugs over time and supplementation as necessary
with parenteral or oral fat-soluble vitamins.
Baseline immunosuppression involved cyclosporine
(Neoral) administration (600 mg/m2/day for pediatric pa-
tients and 15 mg/kg/day for adults). The C2 concentrations
were aimed at 800e1200 ng/mL during the first 6 months,
640e960 ng/mL for up to 1 year, and 480e720 ng/mLthereafter. Intravenous methylprednisolone or oral pred-
nisolone was administered when tolerated, and azathio-
prine (2 mg/kg/day) was discontinued when the patient
had not experienced an episode of severe rejection in the
preceding 6 months. All of the acute rejections were
reversed with steroid pulse therapy.6 Mycophenolate
(Roche, Basel, Switzerland) was used in recipients whose
indications included a more potent immunosuppression and
renal-sparing benefits.7
2.1. Statistical analyses
Data were expressed as mean  standard deviation or
median (range). Survival rates were calculated according to
the KaplaneMeier method and the results were compared
using the log-rank test. All significance tests were two
tailed and differences were considered to be statistically
significant at p < 0.05. Statistical analyses were performed
using SPSS version 10 (SPSS Inc., Chicago, IL, USA).3. Results
Twelve cases were diagnosed with AGS. Nine of the 12 un-
derwent LDLT. Two were brothers who underwent LDLT and
received partial liver allograft. Cholestasis and character-
istic facies were seen in all of the patients. Posterior
embryotoxon was seen in 4/9 (44.4%) patients and butterfly
vertebrae in 3/9 (33.3%) patients. Heart defect (2 with
peripheral pulmonary stenosis and 1 with atrial septal
defect) was seen in 3/9 (33.3%) patients and hep-
atopulmonary syndrome in 2/9 (22.2%) prior to LDLT. Upper
gastrointestinal bleeding was observed in 3/9 (33.3%) and
one had hepatic artery occlusion. Iminodiacetic acid scans
showed no excretion of isotope into the bowel after 24
hours in 4/9 cases (44.4%). Four cases had cholestasis after
60 days of age, whereas five cases had cholestasis prior to
60 days of age. A small gallbladder on ultrasonography
(<1.5 cm length) was noted in 3/9 cases (33.3%); 4/9 cases
(44.4%) showed no excretion of isotope into the bowel,
which suggested a false diagnosis of biliary atresia. Liver
biopsy is needed in all cholestasis cases especially in those
cases where biliary atresia cannot be excluded. All under-
went diagnostic laparotomy and liver biopsy. Liver biopsy
showed characteristic features of paucity of interlobular
bile ducts in all patients. Kasai portoenterostomy was not
performed in any patient prior to being referred for LT.
The mean age at the time of LDLT was 4.6 years (range:
1.0e10.6 years). The total serum bilirubin ranged from
2.0 mg/dL to 15.1 mg/dL. Indications for LT in patients with
AGS were refractory pruritus in all of the nine children,
decompensated cirrhosis in seven patients, recurrent
LDLT for Alagille syndrome 137upper gastrointestinal bleeding in four patients, and hep-
atopulmonary syndrome in two patients. Four cases had
somatic growth retardation prior to LDLT and one died after
LDLT; the other three cases caught up in lineal growth after
LDLT. The first one weighed 11.8 kg (3e10 percentile) at 3
years of age; at 4 years and 5 months of age, the child’s
height was 103 cm (10e25 percentile) and weight was 16 kg
(10e25 percentile). The second child weighed 9.0 kg (<3
percentile) at 2 years and 9 months of age; at 12 years of
age, the patient’s height was 141.6 cm (10e25 percentile)
and weight was 34 kg (10e25 percentile).The third one was
8 kg (<3 percentile) at 1 year, and 153 cm (10e25
percentile) in length with 45 kg (10e25 percentile) at 16
years 5 months old. Renal disease prior to LDLT existed in
2/9 (22.2%) patients.
The 5-year and 20-year overall survival rates after LDLT
were 88.9% and 77.8%, respectively. Patient follow-up
ranged from 4.3 years to 25.7 years after transplant
(Figure 1). The two deaths occurred within the first 30 days
after LDLT. One case died due to hepatic artery thrombosis,
whereas the other died from gastrointestinal bleeding and
intracranial bleeding complicated with brain herniation.4. Discussion
Neonatal cholestatic jaundice is mostly caused by neonatal
giant cell hepatitis. Biliary atresia and AGS also present as
neonatal cholestatic jaundice (8% and 6%, respectively).8
Persistent cholestatic jaundice is associated with poorer
survival with native liver.9 The correct treatment for each
of these clinical entities is different and can significantly
reduce morbidity and mortality from these diseases.1 The
findings of microcornea, posterior embryotoxon, and
anomalous optic discs should suggest the diagnosis of
AGS.10 Liver biopsy shows characteristic features of paucity
of interlobular bile ducts in 76.6%.11 In our nine cases,
44.4% had abnormal findings in the eye, but all showed theFigure 1 Overall survival rates after liver transplantation
(KaplaneMeier method).paucity of interlobular bile ducts and peculiar facies. This
suggests that performing careful physical examination
looking for peculiar characteristics and liver biopsy findings
of interlobular bile duct paucity are important to diagnose
AGS.
Four cases had cholestasis after 60 days of age. The
other five AGS cases had cholestasis prior to the age of 60
days with three children having small gallbladders and four
patients without excretion of isotope into the bowel,
making it difficult to exclude biliary atresia from the diag-
nosis of AGS. The Kasai procedure, although appropriate for
children with biliary atresia, does not benefit children with
AGS and actually appears to worsen outcomes.12,13 None of
our patients had Kasai’s operation. A correct diagnosis can
avoid an unnecessary Kasai portoenterostomy.11 It is re-
ported that mutations in JAG1 can be identified in 70% of
AGS patients.3,14 However, we did not do genetic profiling
studies. We emphasized the importance of the peculiar
facies and liver pathology in the diagnosis of AGS.
In a large series of AGS, heart defects were present in
107 of 117 (91.5%) patients with peripheral pulmonary
stenosis as the most common condition.11 Complex
congenital heart disease and hepatic disease with or
without LT contribute significantly to AGS mortality.5 There
were reported cases of mitral valve regurgitation requiring
valvuloplasty,15 anomalous origin of the left coronary artery
from the pulmonary artery,15 and severe aortic stenosis.16
As reported previously, the frequency of complex cardiac
anomalies was lower in the LT group with AGS compared
with published AGS series (5% and 13%, respectively).17 We
did not see these complex heart conditions in our cases
with routine two-dimensional trans-thoracic echocardiog-
raphy evaluation prior to LT.18 The lower prevalence of
complex cardiac anomalies in LT could result from selection
criteria for transplantation candidates17 or the small num-
ber of AGS patients in our study. This needs further study to
be clarified. We had three congenital heart disease pa-
tients, one atrial septal defect and two peripheral pulmo-
nary stenosis cases. The causes of death of our patients
were without cardiac manifestations of AGS disease, which
is different from previous reports.5,11,15
Actuarial survival rates with the native liver were 51%
and 38% at 10 years and 20 years, respectively.9 The com-
mon factors contributing to the decision for LT were bone
fractures, pruritus, and severe xanthomata.19,20 In our
cases, cholestasis and pruritus with end-stage liver disease
was the most common presentation. We did not find bone
fracture cases.
Most AGS patients die as a result of the complications
related to surgery and heart failure caused by progressive
pulmonary artery stenosis.4,21 One study reported that deaths
in the AGS group mostly occurred within the first 30 days,17
which is consistent with our study where two cases died
after LDLT within 30 days. LDLT is an efficacious treatment
modality for AGS.21 The overall survival rate was 80.4% at 5
years and 62%at 20 years.9,21 Tannuri et al22 reported that AGS
constituted 3.3% of all indications for LDLT in Brazil. Most
patients undergo LT at a median age of 6.5 years.4,19,21 Liver
dysfunction improved in all successful cases.
We should also be careful when procuring partial liver
grafts from close family relatives of AGS patients as these
donors may be AGS patients who were diagnosed. In a
138 C.-N. Lee et alprevious study, the donor operation had to be aborted
because of a liver biopsy that showed paucity of bile ducts
during the operation.23 However, such a finding was not
found in liver pathological analysis in this study.
In summary, we report the clinical characteristics of
nine AGS patients with severe liver disease who had a good
5-year overall survival rate after LT. The clinical features of
AGS are informative. Histological confirmation is important
in the diagnosis.Conflicts of Interest
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